For a patient experiencing two panic attacks per month, is it appropriate to initiate a selective serotonin reuptake inhibitor (SSRI)?

Starting an SSRI for 2 Panic Attacks Per Month

Yes, initiating an SSRI is appropriate for a patient experiencing 2 panic attacks per month, as this frequency meets diagnostic criteria for panic disorder and warrants pharmacological intervention alongside psychotherapy.

Treatment Rationale

The presence of recurrent panic attacks (2 per month qualifies as "recurrent") establishes a diagnosis of panic disorder, which has strong evidence supporting SSRI treatment. The decision to start medication should be based on:

• Frequency and impact: Two panic attacks monthly represents clinically significant distress and functional impairment
• Evidence base: SSRIs demonstrate robust efficacy with a Number Needed to Treat (NNTB) of 7, meaning 7 patients need treatment for 1 to benefit 1
• First-line status: SSRIs are established first-line pharmacological treatment for panic disorder 2, 3

Optimal Treatment Approach

Combination therapy (CBT + SSRI) is superior to either treatment alone and should be offered preferentially 4. The evidence shows:

• Combination CBT plus sertraline improved response, remission, and global function compared to monotherapy (moderate strength of evidence) 4
• Initial treatment response strongly predicts long-term outcomes 4

SSRI Selection and Dosing

Preferred Agents

The strongest evidence supports:

• Paroxetine - demonstrated strongest effect in panic disorder 2
• Fluoxetine - strong efficacy evidence 2
• Sertraline - proven efficacy with good tolerability profile 5

Dosing Strategy

• Start with a subtherapeutic "test" dose to minimize initial anxiety/agitation (a common early SSRI side effect) 4
• Increase slowly at 1-2 week intervals for shorter half-life SSRIs (sertraline, citalopram) 4
• Expect clinically significant improvement by week 6, with maximal benefit by week 12 4
• Higher doses within therapeutic range are associated with greater treatment benefit for SSRIs specifically 6

Critical Safety Considerations

Monitoring Requirements

• Close monitoring for suicidality especially in first months and after dose adjustments (boxed warning through age 24) 4
• Pooled absolute risk: 1% with antidepressants vs 0.2% with placebo (NNH = 143) 4
• Watch for behavioral activation/agitation, particularly in early treatment 4

Common Pitfalls to Avoid

1. Premature discontinuation: Patients may experience initial anxiety worsening before improvement - educate about the 6-week timeline 4
2. Abrupt cessation: Paroxetine, fluvoxamine, and sertraline carry risk of discontinuation syndrome 4
3. Inadequate dosing: Don't hesitate to titrate to higher therapeutic doses if tolerated, as this improves outcomes for SSRIs 6

Alternative Considerations

If SSRIs are contraindicated or not tolerated:

• SNRIs (venlafaxine, duloxetine) are effective alternatives 4
• Benzodiazepines show rapid onset and highest tolerability rankings but should be reserved for short-term use or treatment-resistant cases due to dependence risk 2, 7, 8
• Benzodiazepines can be used temporarily during SSRI initiation to bridge the delayed onset period 8

Expected Outcomes

With SSRI treatment, expect:

• Reduction in panic attack frequency (primary outcome) 5
• Improved global functioning and quality of life 5
• Response rate significantly better than placebo (RR 0.72) 1
• Dropout rate of 88% compared to placebo, indicating good acceptability 1

The evidence clearly supports initiating SSRI therapy at this frequency of panic attacks, particularly when combined with CBT for optimal outcomes.